Efficacy of leucocyte-poor red blood cell suspensions prepared by sedimentation in hydroxyethyl starch.
Hydroxyethyl starch (HES), which is licensed for human use as a plasma volume expander, has red blood cell sedimenting properties similar to high molecular weight dextran (HMWD). The present studies document the effectiveness of commercially available HES in preparing leukocyte-poor red blood cell suspensions (L-PRBCs) from donor whole blood and packed red blood cells stored in CPD up to 120 hours prior to processing. The effect of HES sedimentation on final white blood cell count, on erythrocyte p50 and 2,3-DPG concentration, and on short- and long-term in vivo survival of 72-hour stored donor red cells are described, along with favorable clinical experience with over 300 transfusions of HES-sedimented L-PRBCs. Since the method requires no special equipment, it is immediately available for widespread use.
D001799:Blood Sedimentation; D002469:Cell Separation; D003911:Dextrans / Q000494:pharmacology; D004906:Erythrocyte Count; D004912:Erythrocytes / Q000187:drug effects*; D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects*; D008297:Male; D013213:Starch / Q000031:analogs & derivatives*; D013696:Temperature; D013997:Time Factors
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D013213:Starch